A brief history of DMT
DMT, short for N, N-Dimethyltryptamine, is a naturally-occurring, fast-acting psychoactive molecule. Also described as the…
5 Most Important Psychedelic Clinical Trials in 2022
James Halifax, Psychedelic Spotlight writer and their resident psychedelic investor, recently covered his 5 most…
DMT-Assisted Therapy May Address Root Cause of Major Depression
Gail Dutton of BioSpace.com, a leading online biotechnology source for breaking industry news and expert analysis,…
Small Pharma CEO Peter Rand & CMSO Dr Carol Routledge at the 34th Annual Roth Conference
View Small Pharma’s Fireside Chat Webcast from the 34th Annual Roth Conference Monday, March 14 at 3:30…
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical…
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic…
The Latest in DMT Research: Leading Companies and Key Studies
Truffle Report put together this roundup of the top corporate and scientific developments involving the…
What is DMT therapy?
By Dr Carol Routledge, Chief Medical & Scientific Officer, as originally featured in Drug Science DMT-assisted…
DMT: A Trip To Get Away From Depression?
Ruairi Mackenzie, Senior Science Writer for Technology Networks, recently interviewed Peter Rands, Small Pharma CEO,…
Discussions With FDA Provide Guidance For Phase IIb Clinical Trial Design For DMT-assisted Therapy For Major Depressive Disorder
LONDON, Nov. 15, 2021 -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or…